ORAI1 and pulmonary arterial hypertension: We have showed that Orai1 inhibition, by BTP2, 5J4, or JPIII, corrects in vitro the aberrant phenotypes of human pulmonary artery smooth muscles cells and attenuates in vivo PH in rat models, suggesting that Orai1 inhibition should be considered a relevant therapy in PAH [130].